Bibliography
Hows, M. E. P., Ashmeade, T. E., Billinton, A., Perren, M. J., Austin, A. A., Virley, D. J., Organ, A. J., & Shah, A. J. (2004). High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. Journal of Neuroscience Methods, 137(2), 221â226.
References
21
Referenced
23
10.1002/(SICI)1096-9888(199610)31:10<1101::AID-JMS397>3.0.CO;2-6
/ J. Mass Spectrom. / In vivo hydroxylation of the neurotoxin 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors: electrospray analysis of intra-striatal microdialysates by Boismenu (1996)10.1016/S0021-9673(01)88435-1
/ J. Chromatogr. / Liquid chromatography-mass spectrometry with ionspray and electrospray interfaces in pharmaceutical and biomedical research by Bruins (1991)10.1016/0006-291X(84)91293-2
/ Biochem. Biophys. Res. Commun. / Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase by Chiba (1984){'key': '10.1016/j.jneumeth.2004.02.011_BIB4', 'first-page': '691', 'article-title': 'Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice', 'volume': '257', 'author': 'Giovanni', 'year': '1991', 'journal-title': 'J. Pharmacol. Exp. Ther.'}
/ J. Pharmacol. Exp. Ther. / Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice by Giovanni (1991){'key': '10.1016/j.jneumeth.2004.02.011_BIB5', 'first-page': '151', 'article-title': 'Analysis of neurotoxic metabolite derived from haloperidol in biological samples using LC-APCI/MS and LC-ESI/MS', 'volume': '19', 'author': 'Igarashi', 'year': '1994', 'journal-title': 'Nippon Iyo Masu Supekutoru Gakki Koenshu'}
/ Nippon Iyo Masu Supekutoru Gakki Koenshu / Analysis of neurotoxic metabolite derived from haloperidol in biological samples using LC-APCI/MS and LC-ESI/MS by Igarashi (1994)10.1016/0024-3205(87)90300-6
/ Life Sci. / V. 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity by Irwin (1987)10.1016/0014-2999(84)90740-4
/ Eur. J. Pharmacol. / Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP by Javitch (1984)10.1038/311464a0
/ Nature / Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism by Markey (1984)10.1096/fasebj.12.10.905
/ FASEB J. / Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice by Muralikrishnan (1998)10.1002/syn.10239
/ Synapse / d-Deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity by Muralikrishnan (2003)10.1016/S1566-2772(01)00019-6
/ Clin. Neurosci. Res. / MPTP: a review of its mechanisms of neurotoxicity by Przedborski (2001)10.1016/S0304-3940(03)00577-9
/ Neurosci. Lett. / Calcium channel agonist, (+/−)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice by Samantaray (2003)-
Saporito MS, Thomas BA, Scott RW. MPTP activates c-Jun NH2-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000;1200–8.
(
10.1046/j.1471-4159.2000.0751200.x
) 10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S
/ Synapse / Neuroprotective effects of (+/−)-kavain in the MPTP mouse model of Parkinson’s disease by Schmidt (2001)10.1002/bms.1200130207
/ Biomed. Environ. Mass Spectrom. / Quantification of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion in brain tissue by gas chromatography/mass spectrometry by Shih (1986)10.1007/s007020050171
/ J. Neural. Transm. / Parkinson’s disease: a major hypokinetic basal ganglia disorder by Sian (1999)10.1016/0041-008X(88)90093-2
/ Toxicol. Appl. Pharmacol. / MPTP and MPTP analogs induced cell death in cultured rat hepatocytes involving the formation of pyridinium metabolites by Singh (1998)10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U
/ Synapse / Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease by Teismann (2001)10.1006/neur.1996.0019
/ Neurodegeneration / Striatal MPP+ levels do not necessarily correlate with striatal dopamine levels after MPTP treatment in mice by Vaglini (1996)10.1007/s002100000300
/ Naunyn Schmiedebergs Arch Pharmacol / CGP 3466 protects dopaminergic neurons in lesion models of Parkinson’s disease by Waldmeier (2000)10.1021/ac00184a019
/ Anal Chem. / Quantitative analysis of low molecular weight polar compounds by continuous flow liquid secondary ion tandem mass spectrometry by Wang (1989)
Dates
Type | When |
---|---|
Created | 21 years, 4 months ago (April 21, 2004, 12:14 a.m.) |
Deposited | 6 years, 6 months ago (Feb. 10, 2019, 2:57 a.m.) |
Indexed | 1 year, 4 months ago (April 27, 2024, 9:50 a.m.) |
Issued | 21 years ago (Aug. 1, 2004) |
Published | 21 years ago (Aug. 1, 2004) |
Published Print | 21 years ago (Aug. 1, 2004) |
@article{Hows_2004, title={High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates}, volume={137}, ISSN={0165-0270}, url={http://dx.doi.org/10.1016/j.jneumeth.2004.02.011}, DOI={10.1016/j.jneumeth.2004.02.011}, number={2}, journal={Journal of Neuroscience Methods}, publisher={Elsevier BV}, author={Hows, Mark E.P and Ashmeade, Tracey E and Billinton, Andrew and Perren, Marion J and Austin, Angela A and Virley, David J and Organ, Andrew J and Shah, Ajit J}, year={2004}, month=aug, pages={221–226} }